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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to 
L-theanine from Camellia sinensis (L.) Kuntze (tea) and improvement of 
cognitive function (ID 1104, 1222, 1600, 1601, 1707, 1935, 2004, 2005), 
alleviation of psychological stress (ID 1598, 1601), maintenance of normal 
sleep (ID 1222, 1737, 2004) and reduction of menstrual discomfort 
(ID 1599) pursuant to Article 13(1) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to L-theanine from Camellia sinensis (L.) Kuntze (tea) and improvement of cognitive 
function, alleviation of psychological stress, maintenance of normal sleep and reduction of menstrual 
discomfort. The scientific substantiation is based on the information provided by the Member States 
in the consolidated list of Article 13 health claims and references that EFSA has received from 
Member States or directly from stakeholders. 
The food/constituents that are the subject of the health claims are Camellia sinensis (L.) Kuntze (tea) 
and L-theanine. The Panel considers that while Camellia sinensis (L.) Kuntze (tea) is not sufficiently 
characterised in relation to the claimed effects, L-theanine from Camellia sinensis (L.) Kuntze (tea) is 
sufficiently characterised. 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2008-1843, EFSA-Q-2008-1960, EFSA-Q-2008-2334, 
EFSA-Q-2008-2335, EFSA-Q-2008-2336, EFSA-Q-2008-2337, EFSA-Q-2008-2443, EFSA-Q-2008-2473, EFSA-Q-
2008-2668, EFSA-Q-2008-2737, EFSA-Q-2008-2738, adopted on 08 April 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank for the preparatory work on this scientific opinion: The members of the 
Working Group on Claims: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina 
Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. The members of the Claims Sub-Working Group 
on Mental/Nervous System: Jacques Rigo, Astrid Schloerscheidt, Barbara Stewart-Knox, Sean (J.J.) Strain, and Peter 
Willatts.  
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Improvement of cognitive function 
The claimed effects are “physical and mental stimulation (hydration and caffeine)”, “mental and 
cognitive health”, “cognitive function”, “neurological functions”, “physiological antagonistic against 
caffeine”, and “cognitive performance: focussed attention”. The target population is assumed to be the 
general population. In the context of the proposed wordings and clarifications from Member States, 
the Panel assumes that the claimed effects refer to improvement of cognitive function. The Panel 
considers that improvement of cognitive function is a beneficial physiological effect. 
In weighing the evidence, the Panel took into account that the three human studies from which 
conclusions could be drawn for the scientific substantiation of the claim did not show an effect of 
L-theanine on improvement of cognitive function. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of L-theanine from Camellia Sinensis (L.) Kuntze (tea) 
and improvement of cognitive function. 
Alleviation of psychological stress 
The claimed effects are “relaxation” and “neurological functions”. The target population is assumed 
to be the general population. In the context of the proposed wordings, clarifications from Member 
States and references provided, the Panel assumes that the claimed effects refer to alleviation of 
psychological stress. The Panel considers that alleviation of psychological stress might be a beneficial 
physiological effect. 
No references were provided from which conclusions could be drawn for the scientific substantiation 
of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of L-theanine from Camellia Sinensis (L.) Kuntze (tea) 
and alleviation of psychological stress. 
Maintenance of normal sleep 
The claimed effects are “mental and cognitive health”, and “relaxation”. The target population is 
assumed to be the general population. In the context of the proposed wordings and clarifications from 
Member States, the Panel assumes that the claimed effects refer to the maintenance of normal sleep. 
The Panel considers that maintenance of normal sleep is a beneficial physiological effect. 
No references were provided from which conclusions could be drawn for the scientific substantiation 
of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of L-theanine from Camellia Sinensis (L.) Kuntze (tea) 
and maintenance of normal sleep. 
Reduction of menstrual discomfort  
The claimed effect is “menstrual health”. The target population is assumed to be women with 
premenstrual syndrome. In the context of the proposed wordings, clarifications from Member States 
and references provided, the Panel assumes that the claimed effect refers to reduction of menstrual 
discomfort. The Panel considers that reduction of menstrual discomfort is a beneficial physiological 
effect.  
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No references were provided from which conclusions could be drawn for the scientific substantiation 
of the claim. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of L-theanine from Camellia Sinensis (L.) Kuntze (tea) and reduction of menstrual 
discomfort. 
KEY WORDS 
Camillia sinensis (L.) Kuntze, tea, L-theanine, cognitive function, stress, sleep, menstrual discomfort, health 
claims. 
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The foods/food constituents that are the subject of the health claims are Camellia sinensis (L.) Kuntze 
(tea) and L-theanine. 
Theanine ( -glutamylethylamide) is a glutamic acid analogue present mainly in the tea plant 
(Camellia sinensis), although its presence has also been reported in the mushroom Xerocomus basius. 
Theanine comprises 1-2 % of the dry weight of tea leaves. It is synthesised from glutamic acid and 
ethylamine in tea roots, and accounts for about 50 % of total amino acids in tea (Ekborg-Ott et al., 
1997). L-theanine is a well characterised substance which can be measured by established methods. 
The plant Camellia sinensis (L.) Kuntze is an evergreen shrub of the Theaceae family. Tea is an 
extract of the dried leaves of Camellia sinensis (L.) Kuntze, and it is usually prepared by infusing the 
leaves in hot water. The composition of the tea leaves depends on a variety of factors, including 
climate, season, horticultural practices, and the type and age of the plant. Many kinds of tea are 
produced. Teas can be classified into three major types according to the different degrees of 
fermentation: green (un-fermented), oolong (semi-fermented) and black (fully fermented) (Wang et 
al., 2000). 
The composition of tea drinks greatly depends on the type of leaves used, on the degree of 
fermentation and on the methods of preparation (Astill et al., 2001; Kaszkin et al., 2004). The degree 
of fermentation, the production process, and the method for preparing the tea infusion have not been 
described in relation to the claims. 
Green tea contains polyphenolic compounds, which include flavanols, flavandiols, flavonoids and 
phenolic acids. Most of the polyphenols in green tea are catechins. Epigallo-catechin-3-gallate 
(EGCG) is the most abundant catechin in green tea. In black teas, the most abundant polyphenols are 
tannins, mainly theaflavin and thearubigin (Mukhtar and Ahmad, 2000). Tea extracts/infusions also 
contain variable amounts of potentially active food constituents, such as caffeine or theogallin.  
The Panel considers that while Camellia sinensis (L.) Kuntze (tea) is not sufficiently characterised in 
relation to the claimed effects, L-theanine from Camellia sinensis (L.) Kuntze (tea) is sufficiently 
characterised. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
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2. Relevance of the claimed effect to human health 
2.1. Improvement of cognitive function (ID 1104, 1222, 1600, 1601, 1707, 1935, 2004, 2005)  
The claimed effects are “physical and mental stimulation (hydration and caffeine)”, “mental and 
cognitive health”, “cognitive function”, “neurological functions”, “physiological antagonistic against 
caffeine”, and “cognitive performance: focussed attention”. The Panel assumes that the target 
population is the general population.  
In the context of the proposed wordings and clarifications from Member States, the Panel assumes 
that the claimed effects refer to improvement of cognitive function.  
Cognitive function includes memory, attention (concentration), learning, intelligence and problem 
solving, which are well defined constructs and which can be measured by validated psychometric 
cognitive tests.  
The Panel considers that improvement of cognitive function is a beneficial physiological effect.  
2.2. Alleviation of psychological stress (ID 1598, 1601) 
The claimed effects are “relaxation” and “neurological functions”. The Panel assumes that the target 
population is the general population.  
In the context of the proposed wordings, clarifications from Member States and references provided, 
the Panel assumes that the claimed effects refer to alleviation of psychological stress.  
Psychological stress can be measured by established methods.  
The Panel considers that alleviation of psychological stress might be a beneficial physiological effect. 
2.3. Maintenance of normal sleep (ID 1222, 1737, 2004) 
The claimed effects are “mental and cognitive health”, and “relaxation”. The Panel assumes that the 
target population is the general population.  
In the context of the proposed wordings and clarifications from Member States, the Panel assumes 
that the claimed effects refer to the maintenance of normal sleep. Normal sleep, including normal 
sleep onset latency, efficiency, duration and quality, can be measured by validated methods.  
The Panel considers that maintenance of normal sleep is a beneficial physiological effect. 
2.4. Reduction of menstrual discomfort (ID 1599) 
The claimed effect is “menstrual health”. The Panel assumes that the target population is women with 
premenstrual syndrome.  
In the context of the proposed wordings, clarifications from Member States and references provided, 
the Panel assumes that the claimed effect refers to reduction of menstrual discomfort, which can be 
assessed as changes in the severity of symptoms related to the premenstrual syndrome using validated 
questionnaires. 
The Panel considers that reduction of menstrual discomfort is a beneficial physiological effect.  
L-Theanine from Camellia sinensis (L.) Kuntze (tea) related health claims 
 
8 EFSA Journal 2011;9(6):2238 
3. Scientific substantiation of the claimed effect 
The references provided included a report from an authoritative body on the effects of isolated 
L-theanine given at pharmacological doses, narrative reviews and monographs on the characterisation 
of the Camellia sinensis (L.) Kuntze plant and its byproducts, and a number of narrative reviews 
about the health effects of L-theanine. These publications did not contain original data which could be 
used for the scientific substantiation of the claims. A number of the references provided reported 
either on the effects of food constituents (e.g. caffeine and catechins) other than L-theanine, on the 
effects of L-theanine in combination with other food constituents (e.g. caffeine), or on health 
outcomes (e.g. anxiety, mood, brain chemistry, brain ischaemia, theanine bioavailability, theanine 
toxicity, hydration and cardiovascular health) other than the claimed effects. The Panel considers that 
no conclusions can be drawn from these references for the scientific substantiation of the claims.  
3.1. Improvement of cognitive function (ID 1104, 1222, 1600, 1601, 1707, 1935, 2004, 2005) 
One abstract from a conference proceeding was provided which contained insufficient information for 
a scientific evaluation. Two studies were in Korean and a translation into an EU language was not 
available to the Panel. The Panel considers that no conclusions can be drawn from these references 
for the scientific substantiation of the claim.  
Two human intervention studies (Hindmarch et al., 1998; 2000) in healthy volunteers investigated the 
effects of the consumption of black tea and other beverages on cognition and psychomotor 
performance using a battery of psychometric tests. The Panel notes that the L-theanine content of the 
tea used in these studies was not reported. One cross-sectional study examined the association 
between green tea consumption and cognitive function in 1,003 Japanese subjects aged >70 years 
(Kuriyama et al., 2006). The Panel notes that the L-theanine intake associated with tea consumption 
was not reported. The Panel considers that no conclusions can be drawn from these references for the 
scientific substantiation of the claim. 
A study by Kobayashi et al. (1998) assessed outcomes related to brain electrical activity patterns in 
humans after L-theanine consumption. The Panel notes that brain electrical activity patterns are not 
established measures of cognitive function. The Panel considers that no conclusions can be drawn 
from this reference for the scientific substantiation of the claim. 
A double-blind, cross-over intervention study (Gomez-Ramirez et al., 2007) investigated the effects of 
L-theanine (250 mg in 200 mL water) vs. water alone (placebo) in healthy male and female volunteers 
(n=15). Participants received L-theanine or the placebo on two different test days, the order of which 
was counter balanced across participants. The participants then undertook a standard intersensory 
attentional cueing task (auditory and visual tasks). The reaction time was significantly longer after 
consumption of L-theanine than after consumption of placebo (p<0.05). There were no other effects 
of L-theanine on outcomes of cognitive function. The Panel notes that this study does not show a 
beneficial physiological effect of L-theanine on cognitive outcomes. 
Another double-blind, placebo-controlled trial (Rogers et al., 2008) in healthy students (n=48) 
evaluated the effect on performance of a drink containing L-theanine (200 mg) vs. the same drink 
without L-theanine (placebo) using a visual probe task. Reaction time on the visual probe task was 
significantly longer after consumption of L-theanine than after consumption of placebo (p<0.046). No 
other significant differences on cognitive outcomes were observed between the L-theanine and 
placebo. The Panel notes that this study does not show a beneficial physiological effect of L-theanine 
on cognitive outcomes. 
The references also included a randomised, double-blind, cross-over study (Haskell et al., 2008) 
which investigated the acute effects of a drink containing L-theanine (250 mg) compared to the same 
drink without L-theanine (placebo) on cognitive and mood outcomes in 24 healthy students. A 
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„tailored‟ version of the Cognitive Drug Research battery (CDR Ltd.), a logical reasoning task, a 
sentence verification task and serial subtraction tasks were used to assess cognitive function. 
L-theanine significantly impaired performance on the serial sevens subtraction task compared to 
placebo (p<0.05). No other significant differences on cognitive outcomes were observed between 
L-theanine and placebo periods. The Panel notes that this study does not show a beneficial 
physiological effect of L-theanine on cognitive outcomes. 
In weighing the evidence, the Panel took into account that the three human studies from which 
conclusions could be drawn for the scientific substantiation of the claim did not show an effect of 
L-theanine on improvement of cognitive function. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of L-theanine from Camellia Sinensis (L.) Kuntze (tea) and improvement of cognitive 
function. 
3.2. Alleviation of psychological stress (ID 1598, 1601) 
Among the human studies provided, eight references were published in Japanese or Korean and a 
translation into an EU language was not available to the Panel. The Panel considers that no 
conclusions can be drawn from these references for the scientific substantiation of the claim. 
Among the references provided were conference proceedings for which only the abstracts were 
available. The Panel notes that insufficient information was provided in these abstracts for a full 
scientific evaluation of the studies. 
Two references investigated the effects of L-theanine consumption on brain electrical responses to 
cognitive tasks (Dimpfel et al., 2007; Gomez-Ramirez et al., 2007). The Panel notes that changes in 
brain electrical activity patterns are not considered to be a validated endpoint with respect to 
alleviation of psychological stress. The Panel considers that no conclusions can be drawn from these 
studies for the scientific substantiation of the claim. 
In a randomised, double-blind, placebo-controlled, cross-over (Latin square design) intervention 
study, 16 healthy volunteers (age range: 18-34 years) received a benzodiazepine anxiolytic 
(alprazolam, 1 mg), L-theanine (200 mg) or placebo (unspecified) on three different testing days with 
a minimum wash-out period of seven days (Lu et al., 2004). Measures of anxiety (Beck anxiety 
inventory (BAI), Bond and Lader visual analogue mood scale (VAMS)) were obtained before the 
administration of the treatments, and 2.5 h and 5 h thereafter. The tests were undertaken at rest and 
also under experimentally induced anxiety conditions. The Panel notes that in the absence of direct 
measures of psychological stress, no conclusions can be drawn from measures of anxiety for the 
scientific substantiation of a claim on psychological stress. The Panel considers that no conclusions 
can be drawn from this study for the scientific substantiation of the claim. 
Another randomised, double-blind, placebo-controlled, cross-over (Latin square design) study 
examined psychological and physiological responses to stress in 12 healthy male volunteers (age 
range: 20-25 years) after consumption of L-theanine (200 mg dissolved in 100 mL of water), placebo 
(water alone), or when receiving no treatment in four test sessions (Kimura et al., 2007). Each 
experimental session began with a 20 min rest period, followed by a mental arithmetic task for 20 min 
to induce stress, and then by two rest periods of 10 min. L-theanine was administered either at the 
beginning of the experiment (test 1) or immediately before the arithmetic task (test 2), whereas 
placebo was administered only at the beginning of the experiment (test 3). In an additional 
experimental session (test 4), no treatment was given and a rest period was substituted for the 
arithmetic task (control). At the end of each test session, subjective stress was measured using a visual 
analogue scale, and anxiety was evaluated with the state scale of the state-trait anxiety inventory 
L-Theanine from Camellia sinensis (L.) Kuntze (tea) related health claims 
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(STAI). Heart rate (measured continuously), heart rate variability (measured continuously) and 
saliva-IgA (obtained at the end of each test session) were also assessed. The Panel notes that the 
measure of psychological stress used in this study was unspecified, and that in the absence of direct 
measures of psychological stress no conclusions can be drawn from measures of anxiety for the 
scientific substantiation of a claim on psychological stress. The Panel considers that no conclusions 
can be drawn from this study for the scientific substantiation of the claim.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of L-theanine from Camellia Sinensis (L.) Kuntze (tea) and alleviation of psychological 
stress. 
3.3. Maintenance of normal sleep (ID 1222, 1737, 2004) 
One human study in healthy volunteers (Hindmarch et al., 2000) which investigated the effects of the 
consumption of black tea on sleep was provided. The Panel notes that the L-theanine content of the 
tea used in this study was not specified. The Panel considers that no conclusions can be drawn from 
this reference for the scientific substantiation of the claim. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of L-theanine from Camellia Sinensis (L.) Kuntze (tea) and maintenance of normal 
sleep. 
3.4. Reduction of menstrual discomfort (ID 1599) 
The references provided included a book chapter and a narrative review which did not contain any 
original data for the scientific substantiation of the claim. Another research paper reported on the 
effects of L-theanine consumption on health outcomes (i.e. brain electrophysiological activity) 
unrelated to premenstrual syndrome. One study was published in Japanese and a translation into an 
EU language was not available to the Panel. The Panel considers that no conclusions can be drawn 
from these references for the scientific substantiation of the claim. 
An abstract, published in conference proceedings, reported on the effect of L-theanine on the 
premenstrual syndrome (Terashima and Yokogoshi, 2001). The information provided regarding the 
study design, methodology and statistical analyses was insufficient for a full scientific evaluation. The 
Panel considers that no conclusions can be drawn from this reference for the scientific substantiation 
of the claim. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of L-theanine from Camellia Sinensis (L.) Kuntze (tea) and reduction of menstrual 
discomfort. 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food, Camellia sinensis (L.) Kuntze (tea), which is the subject of the health claims, is not 
sufficiently characterised in relation to the claimed effects, whereas L-theanine from Camellia 
sinensis (L.) Kuntze (tea) is sufficiently characterised.  
Improvement of cognitive function (ID 1104, 1222, 1600, 1601, 1707, 1935, 2004, 2005) 
 The claimed effects are “physical and mental stimulation (hydration and caffeine)”, “mental 
and cognitive health”, “cognitive function”, “neurological functions”, “physiological 
L-Theanine from Camellia sinensis (L.) Kuntze (tea) related health claims 
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antagonistic against caffeine”, and “cognitive performance: focussed attention”. The target 
population is assumed to be the general population. Improvement of cognitive function is a 
beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
L-theanine from Camellia Sinensis (L.) Kuntze (tea) and improvement of cognitive function. 
Alleviation of psychological stress (ID 1598, 1601) 
 The claimed effects are “relaxation” and “neurological functions”. The target population is 
assumed to be the general population. In the context of the proposed wordings, clarifications 
from Member States and references provided, it is assumed that the claimed effects refer to 
alleviation of psychological stress. Alleviation of psychological stress might be a beneficial 
physiological effect. 
 The Panel concludes that a cause and effect relationship has not been established between the 
consumption of L-theanine from Camellia Sinensis (L.) Kuntze (tea) and alleviation of 
psychological stress. 
Maintenance of normal sleep (ID 1222, 1737, 2004) 
 The claimed effects are “mental and cognitive health”, and “relaxation”. The target 
population is assumed to be the general population. In the context of the proposed wordings 
and clarifications from Member States, it is assumed that the claimed effects refer to the 
maintenance of normal sleep. Maintenance of normal sleep is a beneficial physiological 
effect. 
 The Panel concludes that a cause and effect relationship has not been established between the 
consumption of L-theanine from Camellia Sinensis (L.) Kuntze (tea) and maintenance of 
normal sleep. 
Reduction of menstrual discomfort (ID 1599) 
 The claimed effect is “menstrual health”. The target population is assumed to be women with 
premenstrual syndrome. Reduction of menstrual discomfort is a beneficial physiological 
effect. 
 The Panel concludes that a cause and effect relationship has not been established between the 
consumption of L-theanine from Camellia Sinensis (L.) Kuntze (tea) and reduction of 
menstrual discomfort. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-1843, 
EFSA-Q-2008-1960, EFSA-Q-2008-2334, EFSA-Q-2008-2335, EFSA-Q-2008-2336, EFSA-Q-2008-
2337, EFSA-Q-2008-2443, EFSA-Q-2008-2473, EFSA-Q-2008-2668, EFSA-Q-2008-2737, EFSA-Q-
2008-2738). The scientific substantiation is based on the information provided by the Member States 
in the consolidated list of Article 13 health claims and references that EFSA has received from 
Member States or directly from stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
6
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health". 
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be: 
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3). 
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
7
  
Foods are commonly involved in many different functions
8
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent. 
                                                     
6 OJ L12, 18/01/2007 
7 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
8 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).  
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect. 
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects: 
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent. 
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
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consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to L-theanine from Camellia sinensis (L.) Kuntze (tea), 
including conditions of use from similar claims, as proposed in the Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
1104 Camelia sinensis 
(Common Name : Tea) 
Physical and mental 
stimulation 
(hydration and caffeine) 
Tea helps refresh body and 
mind/Tea helps to revive 
you/Tea helps keeping you 
alert  
Conditions of use 
- 200ml (1 cup) of black tea (equivalent to 0.4- 0.5g/serving tea solids)  
- Blätter, Knospen /Äquivalent von 3 - 6 Tassen Tee oder 45-200 mg L-Theanin pro Tag 
- No Milk/Sugar added 
ID Food or Food constituent Health Relationship Proposed wording 
1222 Camellia sinensis (Common 
Name : Tea) 
Mental and cognitive health Supports natural sleep 
/relaxing /promotes 
concentration /theanine from 
thea contributes to soothing 
effect 
Conditions of use 
- Leaf, bud / The equivalent of 3-6 cups of tea or 45-200 mg of L-theanine per day 
- At least 30 mg of the green tea extract 
- Not less than 10 mg of Camellia sinensis leaf extract 5:1 a day 
ID Food or Food constituent Health Relationship Proposed wording 
1598 L-theanine Relaxation 
Clarification provided 
- Promotes relaxation/helps 
to promote relaxation 
without drowsiness through 
modulating resting state of 
brains (in which EEG is in 
alpha frequency band).- 
Reduces/helps to reduce 
stressed out feeling by 
modulating resting state of 
brains- Eases nervousness 
due to common every day 
overwork and fatigue 
through modulating resting 
state of rains (in which EEG 
is in alpha frequency band 
which also enhances focused 
attentional process).- 
Calming down and relaxing 
through modulating resting 
state of brains.- Gently 
-help relaxation without 
drowsiness. 
-Stress relief. 
-Physical stress relief. 
-Relax from fatigue. 
-Support relation for optimal 
mental and physical well-
being. 
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soothe away the tension (by 
modulating resting state of 
brains).- Calmative (through 
modulating resting state of 
brains).- Resolving that 
irritability that ruins your day 
(by modulating resting state 
of brains).- Reduces 
restlessness (by modulating 
resting state of brains).- 
Reduces nervous irritability 
by modulating resting state 
of brains.- When you're 
under occasional stress, 
helps you work relaxed 
(through modulating resting 
state of brains).   - Helps 
restore mental alertness or 
wakefulness when 
experiencing fatigue or 
drowsiness (should not imply 
treatment of chronic fatigue 
or daytime drowsiness as 
these are symptoms of 
chronic fatigue syndrome 
and narcolepsy, respectively) 
through modulating resting 
state of brains, in which EEG 
is in alpha frequency band 
which also enhances focused 
attentional process.- Helps 
learning performance (by 
enhancing alpha attention 
effect).- Helps to improve 
concentration (by enhancing 
alpha attention effect).- 
Helps to improve attention 
(by enhancing alpha 
attention effect).  
Conditions of use 
- 100 – 200 mg a day 
- Food supplement with 100-300mg of L-theanine (Suntheanine) in the daily dose. 
- Recommended dosage: 50~250 mg  JFFA approved for unlimited use in foods with the 
exception of infant foods. An amino acid from tea, present in the range of 4.30 mg to 24 mg 
per gram of tea. A cup of tea may contain 13.0 to 75.0 mg of theanine  Safety studies such 
as 28 Day Subacute Toxicity Study, (2,000 mg/kg/day for 28 days) 78 Week Evaluation of 
Toxicity and Carcinogenicity Acute Toxicity/LD-50 Determination (5,000 mg/kg/day – 7 
days) Ames Salmonella/Microsome Plate Test for Mutagenicity 2 week Dietary Range 
Finding Toxicity Study in Rats (6500 mg/kg/day) 13 week dietary toxicity and toxicokinetic 
study in rats (4000mg/kg/day), proved safety of L-theanine. 
- Food supplement with 75-225 mg of theanine and oat shoot extract (equivalent to 400-1200 
mg of fresh oat shoot) in the daily dose. 
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ID Food or Food constituent Health Relationship Proposed wording 
1599 L-theanine Menstrual health 
Clarification provided 
MAS (Manifest anxiety 
scale) based surveys showed 
that L-theanine relieved the 
physical and mental stress in 
several women during their 
menstrual periods. 
Promoting the brain alpha 
waves and attenuating the 
sympathetic nervous system: 
Helps to improve physical 
and psychological symptoms 
associated with premenstrual 
syndrome (PMS) Support for 
normal physical and mental 
state during premenstrual 
period Improve aggression 
and physcial stress during 
premenstrual period. Support 
painless and stress free 
menstrual periods. Improve 
quality of life during 
menstrual cycle  
-help to maintained a calm and 
relaxed physical and 
psychological state pre- menstrual period.   
-support in premenstrual 
syndrome. Support a normal 
healthy attitude during 
menstrual cycle. 
Conditions of use 
- 200mg/day 
ID Food or Food constituent Health Relationship Proposed wording 
1600 L- theanine Cognitive function - Help learning performance. 
- Help to improve 
concentration. 
- Help to improve attention. 
- Sports support 
Conditions of use 
- 200 mg 
ID Food or Food constituent Health Relationship Proposed wording 
1601 L-theanine Neurological functions 
Clarification provided 
Helps the brain to protect 
from neuro toxins: Helps to 
attenuate sympathetic 
nervous activation to induce 
anti-stress effects Help the 
brain to protect from neuron 
damage L-theanine has 
antogonist against Caffeine 
- Neuroprotective. 
-  Brain support 
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induced convulsion and 
exitation and Glutamate 
induced apotposis and 
neuron damage. L-theanine 
protects against ischemic 
refusion induced neuronal 
death. L-theanine improves 
the cognitive function. 
Important for neuro-
protection and normal brain 
function. 
Conditions of use 
- Up to 1 mg/kg BW in animal studies 
ID Food or Food constituent Health Relationship Proposed wording 
1707 Teanine Cognitive function 
Clarification provided 
Neuromuscolar system 
It heps relaz status without 
reducing the “alert status”; It 
hepls against nervous tension 
 
Conditions of use 
- 12,5 mg/sachet 
ID Food or Food constituent Health Relationship Proposed wording 
1737 L-Theanine Relaxation 
Clarification provided 
Helps promote the onset of 
sleep. Reduces psychological 
and physiological stress 
responses via the inhibition 
of cortical neuron excitation 
and increased alpha-wave 
brian activity. 
helps to maintain an optimal 
relaxation; helps to support the 
relaxation ; helps to maintain a 
healthy sleep 
 
Conditions of use 
- 200 mg 
- 200 mg/day 
ID Food or Food constituent Health Relationship Proposed wording 




reduces the convulsions and 
exitation induced by caffeine 
(antogosinst effect). 
Improves the mood, focus 
and cognitive functions. 
Reduced the reaction time in 
visual probe task, enhanced 
hit rate, target dicriminibility, 
Caffeine antogonist 
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attention and ignoring 
distraction. 
Conditions of use 
- 5-10 micro mole/kg 
ID Food or Food constituent Health Relationship Proposed wording 
2004 Camellia sinensis (Common 
Name : Tea) 
Mental and cognitive health 
 
Supports natural sleep 
/relaxing /promotes 
concentration /theanine from 
thea contributes to soothing 
effect 
Conditions of use 
- Leaf, bud / The equivalent of 3-6 cups of tea or 45-200 mg of L-theanine per day 
- Liście, pąk/ równowartość 3 do 6 szklanek herbaty lub 45-200 mg L-teaniny na dzień 
ID Food or Food constituent Health Relationship Proposed wording 




Tea helps you focus/ 
concentrate/ be less distracted/ 
helps you to be sharp/ helps 
you to be alert - Tea contains 
theanine/ Theanine stimulates 
alpha brainwaves which are 
associated with a relaxed but 
alert mental state;  
Theanine helps relax your 
mind/helps you to be relaxed; 
promotes a restful, relaxed 
state; calms and clears the 
mind 
Conditions of use 
- 2 to 3 cups of black tea (providing > 45 mg L-theanine) 
- 2 do 3 szklanek czarnej herbaty (dostarczających >45 mg L-teaniny) 
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GLOSSARY AND ABBREVIATIONS 
BAI  Beck anxiety inventory 
EGCG  Epigallo-catechin-3-gallate 
STAI  State-trait anxiety inventory 
VAMS  Visual analogue mood scale 
